Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.
Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multicenter, double-blinded study with the first patient screened in August 2022 to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized